Continuous Glucose Monitoring Beyond Type 1: What the Evidence Actually Shows

Continuous glucose monitoring was first developed for people with type 1 diabetes, and it remains a cornerstone of T1D care. But in recent years, CGM technology has rapidly expanded into new populations: people with type 2 diabetes, those with prediabetes, and even individuals without diabetes at all.

As CGM use has broadened, an important question has emerged: Does the evidence support using it in all these new groups? A major review published in JAMA Internal Medicine set out to answer that question by examining what clinical research actually shows about CGM benefits across different populations.

For adults with type 2 diabetes, the evidence is clearest. Randomized controlled trials consistently found that people using CGM had lower hemoglobin A1c levels compared to those using traditional finger-stick testing or standard care.

The average improvement was modest—around 0.3% reduction in A1c. While that might sound small, the review notes that some patients experienced considerably larger improvements. This suggests that CGM helps many people with type 2 diabetes, though not everyone to the same degree.

For other groups, the picture is less clear. People with type 2 diabetes who are not taking glucose-lowering medications, those with prediabetes, and those with obesity have limited evidence supporting CGM use. The available research doesn't yet show strong benefits in these populations.

This distinction matters. It means that the case for CGM is stronger in some populations than others, and expanding access without good evidence could lead to unnecessary use in groups unlikely to benefit.

The review's main conclusion is practical: CGM should be deployed based on individual patient circumstances, goals, and clinical context—not as a default intervention for everyone. In other words, the question shouldn't be 'Should this person use CGM?' but rather 'Does this person have a specific problem that CGM can help solve?'

This approach aims to ensure that people most likely to benefit from CGM actually have access to it, while avoiding overuse in populations where the evidence doesn't support it. It's a reminder that newer technology isn't always better for everyone, and that thoughtful, personalized decisions matter more than broad adoption.

Source: JAMA internal medicine. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.